{"id":2486,"date":"2017-07-01T12:01:00","date_gmt":"2017-07-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/infliximab-versus-biosimilar-ct-p13"},"modified":"2017-07-01T12:01:00","modified_gmt":"2017-07-01T10:01:00","slug":"infliximab-versus-biosimilar-ct-p13","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/infliximab-versus-biosimilar-ct-p13","title":{"rendered":"Infliximab versus Biosimilar CT-P13"},"content":{"rendered":"<p>Infliximab (Remicade\u00ae) ist ein chim\u00e4rer, human-muriner monoklonaler IgG1-Antik\u00f6rper gegen l\u00f6sliche und transmembrane Formen des Tumor-Nekrose-Faktors alpha (TNF-\u03b1). Er ist zugelassen zur Behandlung von Patienten mit Morbus Crohn, Colitis ulcerosa, Spondylarthritis (M. Bechterew), Rheumatoider Arthritis, Psoriasis-Arthritis und chronischer Plaque-Psoriasis (1, 2). Insgesamt bedeutet die Behandlung dieser Erkrankungen mit einem TNF-\u03b1-Hemmer einen deutlichen Fortschritt (1). Aber der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Infliximab (Remicade\u00ae) ist ein chim\u00e4rer, human-muriner monoklonaler IgG1-Antik\u00f6rper gegen l\u00f6sliche und transmembrane Formen des Tumor-Nekrose-Faktors alpha (TNF-\u03b1). Er ist zugelassen zur Behandlung von Patienten mit Morbus Crohn, Colitis ulcerosa, Spondylarthritis (M. Bechterew), Rheumatoider Arthritis, Psoriasis-Arthritis und chronischer Plaque-Psoriasis (1, 2). Insgesamt bedeutet die Behandlung dieser Erkrankungen mit einem TNF-\u03b1-Hemmer einen deutlichen Fortschritt (1). Aber der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1575,1983,1984,2873,463,1188,4906,1267,1580,465,4907,4909,4908,340,1583,1578,1067,1981,1980,1979,1263,1262,1257,1260,1261,1259,1258,1264],"class_list":["post-2486","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ankylosierende-spondylitis","tag-biologika","tag-biopharmazeutika","tag-biosimilars","tag-chronisch-entzuendliche-darmerkrankungen","tag-colitis-ulcerosa","tag-ct-p13","tag-infliximab","tag-m-bechterew","tag-m-crohn","tag-nor-switch-studie","tag-planetas-studie","tag-planetra-studie","tag-psoriasis","tag-psoriasis-arthritis","tag-psoriasisarthritis","tag-rheumatoide-arthritis","tag-spondylarthritis","tag-spondylarthropathien","tag-spondyloarthritis","tag-tnf-alpha-antagonisten","tag-tnf-alpha-antikoerper","tag-tnf-alpha-blocker","tag-tnf-alpha-hemmer","tag-tumor-nekrose-faktor-antagonisten","tag-tumor-nekrose-faktor-antikoerper","tag-tumor-nekrose-faktor-blocker","tag-tumor-nekrose-faktor-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2486"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2486\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}